Citation: | LIU Mingtao, PANG Yanrong, ZHAO Liang, WEN Zhongzheng, HOU Guoqing. Expression and clinical significance of microRNA-210 and lipoprotein-associated phospholipase A2 in patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(21): 39-42. DOI: 10.7619/jcmp.20212085 |
[1] |
KARAKAS M, SCHULTE C, APPELBAUM S, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study[J]. Eur Heart J, 2017, 38(7): 516-523. http://www.onacademic.com/detail/journal_1000039191722410_5bab.html
|
[2] |
YANG L, WANG H, ZHANG Y, et al. The prognostic value of lipoprotein-associated phospholipase A2 in the long-term care of patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Clin Appl Thromb Hemost, 2018, 24(5): 822-827. doi: 10.1177/1076029617737837
|
[3] |
YANG L, LIU Y, WANG S, et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res, 2017, 45(1): 159-169. doi: 10.1177/0300060516678145
|
[4] |
DE MAURI A, VIDALI M, CHIARINOTTI D, et al. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients[J]. J Nephrol, 2019, 32(2): 283-288. doi: 10.1007/s40620-018-0521-3
|
[5] |
ZHANG H, HAO J, SUN X, et al. Circulating pro-angiogenic micro-ribonucleic acid in patients with coronary heart disease[J]. Interact Cardiovasc Thorac Surg, 2018, 27(3): 336-342. http://www.onacademic.com/detail/journal_1000040263291210_a8df.html
|
[6] |
李馨航, 李沅洋, 孙旭森, 等. R2CHA2DS2-VASc评分对急性心肌梗死后发生急性心力衰竭风险的预测价值[J]. 天津医药, 2021, 49(3): 281-284. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202103013.htm
|
[7] |
HU Y, LI T T, ZHOU W, et al. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease[J]. Diabetes Res Clin Pract, 2019, 150: 194-201. doi: 10.1016/j.diabres.2019.03.026
|
[8] |
YOUNUS A, HUMAYUN C, AHMAD R, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review[J]. J Clin Lipidol, 2017, 11(2): 328-337. doi: 10.1016/j.jacl.2017.02.005
|
[9] |
李道麟, 董平栓, 赵江峰, 等. 冠心病患者血清Lp-PLA2、sdLDL-C水平变化及临床意义[J]. 中国循证心血管医学杂志, 2019, 11(3): 316-319. doi: 10.3969/j.issn.1674-4055.2019.03.12
|
[10] |
ZHENG D, CAI A, XU R, et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia[J]. Arch Med Sci, 2018, 14(3): 629-634. doi: 10.5114/aoms.2017.69494
|
[11] |
TORIBIO M, FITCH K V, STONE L, et al. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial[J]. EBioMedicine, 2018, 35: 58-66. doi: 10.1016/j.ebiom.2018.08.039
|
[12] |
ZHANG M M, ZHANG C G, YANG C J, et al. The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction[J]. Eur Rev Med Pharmacol Sci, 2019, 23(9): 3960-3966. http://www.ncbi.nlm.nih.gov/pubmed/31115024
|